ArticleMedical microbiology and immunology2026
The small GTPase Rab5 inhibits actin polymerization mediated by the Legionella pneumophila effector VipA.
Article in Medical microbiology and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Legionella pneumophila is a facultative intracellular bacterium that causes Legionnaires’ disease, one of the most severe manifestations of atypical pneumonia. The capacity of L. pneumophila to cause disease relates with its ability to survive and multiply inside a membrane-bound compartment, the Legionella-containing vacuole (LCV). The remodeling of the LCV into a replication-competent compartment requires the Icm/Dot type 4 secretion system, that translocates over 300 bacterial effector proteins into host cells. Their action is concerted spatially and timely in order to modulate a multitude of host cell targets and thus ensure LCV segregation from the phagolysosomal pathway. The L. pneumophila effector VipA associates with early endosomes and promotes the nucleation of new actin filaments in vitro. Additionally, ectopically produced VipA impairs vesicle trafficking in Saccharomyces cerevisiae. However, the mechanisms underlying its association with the endocytic pathway have remained elusive. In this work, we sought the molecular interacting partners of VipA in early endosomes and explored the effects of this association. We found that VipA interacts directly with two key components of these organelles, the membrane lipid phosphoinositide 3-phosphate (PI3P) and the small GTPase Rab5. Binding to Rab5 requires the NH2-terminal region of VipA but not the COOH-terminal/actin-binding region. Furthermore, binding to Rab5 inhibits VipA-mediated actin polymerization by preventing de novo actin filament formation. These findings offer new insights into the mode of action of VipA and underscore the intricate network of interactions between L. pneumophila effectors and their host cell targets, namely in the endocytic pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.